I am a
Home I AM A Search Login

Papers of the Week

2022 Sep 03

Curr Opin Pharmacol


Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome.


Algera JP, Törnblom H, Simrén M
Curr Opin Pharmacol. 2022 Sep 03; 66:102284.
PMID: 36067685.


Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction affecting 4% of the world's population. Patients with IBS experience chronic or recurrent abdominal pain in combination with altered bowel habits (diarrhea and/or constipation), and have reduced quality of life. Despite the high prevalence and substantial burden of IBS, its pathophysiology is incompletely understood and remains to be elucidated. The importance of the gut microenvironment has been highlighted in IBS, as there are signs that the gut microbiota of patients differs from healthy controls. Recent studies have aimed to alter the gut microbiota and thereby, attempted to alleviate gastrointestinal symptoms in IBS patients. We highlighted recent advances in common treatments that are targeting the luminal gut microbiota in IBS.